Seroconversion following nonoccupational postexposure prophylaxis against HIV
- PMID: 16231265
- DOI: 10.1086/497268
Seroconversion following nonoccupational postexposure prophylaxis against HIV
Abstract
Background: The efficacy of antiretroviral postexposure prophylaxis (PEP) against infection with human immunodeficiency virus (HIV) following occupational exposures has prompted the use of PEP after nonoccupational exposures. There are, however, important differences between occupational and nonoccupational exposures, and the effectiveness of PEP following nonoccupational exposure is unknown. We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP.
Methods: HIV uninfected individuals reporting potential sexual or injection drug use exposures to HIV in the preceding 72 h received a 28-day regimen of antiretroviral therapy and counseling in a nonrandomized trial. The level of HIV antibody was measured 12 weeks after PEP initiation.
Results: Of 877 exposed subjects, 702 were evaluable 12 weeks after exposure. Seroconversion was detected in 7 subjects (1%; 95% confidence interval, 0.4%-2%). Three seroconverters reported having no exposures after PEP initiation and, thus, probably represent evidence of chemoprophylactic failure. In the other 4 subjects, additional exposures to HIV after PEP initiation or detection of HIV RNA in plasma specimens obtained at baseline precluded determination of the source of seroconversion. No exposure source was available to assess genetic concordance with the seroconverter's virus.
Conclusions: As for occupational exposure, PEP is not completely effective in preventing HIV infection following nonoccupational exposure. Therefore, primary prevention remains essential. In contrast to the occupational setting, the potential source of exposure is rarely available for testing in the nonoccupational setting, and exposures are often not isolated. Thus, it is often impossible to determine whether seroconversion resulted from failure of PEP or from other exposures, posing difficulties for future comparative studies seeking to evaluate the effectiveness of PEP.
Comment in
-
HIV antiretroviral postexposure prophylaxis: a cautionary note.Clin Infect Dis. 2005 Nov 15;41(10):1514-6. doi: 10.1086/497274. Epub 2005 Oct 13. Clin Infect Dis. 2005. PMID: 16231266 No abstract available.
Similar articles
-
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.J Infect Dis. 2001 Mar 1;183(5):707-14. doi: 10.1086/318829. Epub 2001 Feb 1. J Infect Dis. 2001. PMID: 11181146
-
Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.Arch Intern Med. 2004 Jan 12;164(1):46-54. doi: 10.1001/archinte.164.1.46. Arch Intern Med. 2004. PMID: 14718321
-
Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.J Infect Dis. 2001 Dec 15;184(12):1608-12. doi: 10.1086/324580. Epub 2001 Dec 3. J Infect Dis. 2001. PMID: 11740738
-
Postexposure prophylaxis after sexual exposure to HIV.Curr Opin Infect Dis. 2007 Feb;20(1):39-46. doi: 10.1097/QCO.0b013e328012c5e0. Curr Opin Infect Dis. 2007. PMID: 17197880 Review.
-
Postexposure prophylaxis against human immunodeficiency virus.Am Fam Physician. 2010 Jul 15;82(2):161-6. Am Fam Physician. 2010. PMID: 20642270 Review.
Cited by
-
Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies.Ann Med. 2023;55(2):2288309. doi: 10.1080/07853890.2023.2288309. Epub 2023 Dec 8. Ann Med. 2023. PMID: 38065681 Free PMC article.
-
The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles.Viruses. 2022 Dec 30;15(1):107. doi: 10.3390/v15010107. Viruses. 2022. PMID: 36680147 Free PMC article. Review.
-
PrEP in the Context of Other HIV Risk Reduction Strategies Among Men Who Have Sex with Men: Results from the Flash! PrEP in Europe Survey.Arch Sex Behav. 2022 Jul;51(5):2451-2464. doi: 10.1007/s10508-022-02322-7. Epub 2022 Jun 20. Arch Sex Behav. 2022. PMID: 35725849 Free PMC article.
-
The ongoing HIV epidemic in American youth: challenges and opportunities.Mhealth. 2021 Apr 20;7:33. doi: 10.21037/mhealth-20-42. eCollection 2021. Mhealth. 2021. PMID: 33898602 Free PMC article. Review.
-
[HIV pre-exposure prophylaxis care in intersectoral collaboration : Interim analysis of a monocentric, prospective study in Germany].Hautarzt. 2020 Mar;71(3):211-218. doi: 10.1007/s00105-020-04545-y. Hautarzt. 2020. PMID: 32125439 German.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
